DEROYAL INDUSTRIES, INC.

Elucid Strengthens Leadership Team to Launch AI-Powered Atherosclerosis Analysis Software PlaqueIQ

3 months ago

• Elucid appoints key executives including Dr. Amir Ahmadi as chief scientific advisor to spearhead the commercial launch of FDA-cleared PlaqueIQ software for atherosclerosis analysis. • PlaqueIQ becomes the first FDA-cleared non-invasive software that quantifies and classifies plaque morphology based on histology, enabling physicians to make patient-specific treatment decisions. • Recent CMS reimbursement changes double CCTA payments and expand AI-enabled plaque analysis coverage to over 70% of eligible Medicare patients, significantly improving healthcare accessibility.